High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes (Q33349413)

26 July 2017

title

High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes (English)

1 reference

26 July 2017

1 reference

Selim Firat

1

1 reference

26 July 2017

Kevin Murray

series ordinal

2

1 reference

26 July 2017

Beth Erickson

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

International Journal of Radiation Oncology Biology Physics

26 July 2017

published in

1 reference

26 July 2017

volume

57

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

201-207

1 reference

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Prognostic factors in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Integrating radiation therapy in the curative management of ovarian cancer: current issues and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Chemotherapy for ovarian cancer: current concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Epithelial ovarian cancer: the role of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

WART revisited: the treatment of epithelial ovarian cancer by whole abdominal radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Postoperative abdominopelvic radiation therapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Primary adjuvant whole abdominal irradiation in ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Total abdominal and pelvic radiotherapy in the management of early stage ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Whole abdominal irradiation by a moving-strip technique for patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Postoperative radiation therapy for epithelial ovarian cancer: the curative role based on a 24-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Is there place for radiotherapy in the treatment of advanced ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Abdominopelvic radiotherapy in ovarian cancer. A 10-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Palliative radiotherapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Selective irradiation for the treatment of recurrent ovarian carcinoma involving the vagina or rectum

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Treatment of early epithelial ovarian cancer with chemotherapy and abdominopelvic radiotherapy: results of a prospective treatment protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Gynecologic Oncology Group of the Comprehensive Cancer Center

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Cisplatin-based chemotherapy for stage II ovarian adenocarcinoma: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked stage I, II, and III ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Analysis of postoperative radiation therapy in stage I through III epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Determinants of survival of patients with epithelial ovarian carcinoma following whole abdomen irradiation (WAR).

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

Complications of whole abdominal and pelvic radiotherapy following chemotherapy for advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900510-8

7 January 2021

10.1016/S0360-3016(03)00510-8

Identifiers

DOI

1 reference

26 July 2017

1 reference